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. This is an open access article under1. Introduction
Circulating osteogenic precursor (COP) cells are a relatively new en-
tity in the ﬁeld of stem cell and bone biology. They are deﬁned as a pop-
ulation of ﬂuid-phase, blood-borne cells with the capacity for
osteogenesis, or differentiation into mesenchymal tissues. Such cellsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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been used to reference them, including circulating osteoprogenitors, cir-
culating mesenchymal stem cells (cMSCs), monocyte-derived mesen-
chymal precursors, and circulating skeletal stem cells, amongst others.
However, there is little consensus between the studies regarding their
characterization,with individual research groups using a range of differ-
ent, and at times conﬂicting, cellularmarkers and criteria to deﬁne these
cells. This contradiction and disagreement has diminished the applica-
bility of the current research base and limited progress in the ﬁeld.
Herein, we analyze the literature describing COP cells to provide a
clearer understanding of their characterization, as well as to compare
them with the better-known bone marrow MSCs. We then identify
areas for further research to allow a more comprehensive analysis of
the biological identity and behavior of these cells.
2. Search strategy and selection criteria
The studies used in this reviewwere identiﬁed through search of the
MEDLINE and PubMed databases, using all or part of the search terms
‘Circulating Osteogenic Precursor’, ‘Circulating Mesenchymal Stem cell’
‘Circulating Osteoprogenitor’, and ‘Circulating Stem Cell’, connected by
the Boolean operator ‘OR’, identifying 1048 search items. Examination
of paper titles and removal of duplicates yielded 72 included studies.
Resulting abstracts were studied for suitability yielding a total of 37 in-
cluded studies. Finally, reference lists of included the included studiesFig. 1. Flow chart of paper inclusiowere searched for further possible inclusions, resulting in the inclusion
of an additional two papers, bringing the total to 39 (Fig. 1).
3. Origins of the osteoblast – A historical perspective
Ossiﬁcation and maintenance of the skeleton has long been known
to involve a dichotomous relationship between bone forming osteo-
blasts and resorbing osteoclasts. Osteoblasts were identiﬁed on the ex-
ternal surface of bone, but it was unclear where they come from and
how they are regenerated, as they are unable to undergo mitotic divi-
sion. Osteoclasts were identiﬁed in the circulation in the 1870's [1],
and thought to be osteoblasts that had fused with a neighboring chon-
drocyte. This connection sparked the idea of a circulating osteoblastic
progenitor cell, as a means of answering the above question, however,
despite repeated efforts these were never found. Little progress was
made in ﬁnding an osteoblastic precursor until nearly a century later,
when Urist [2] stimulated histiocytes into osteogenesis via
autoinduction, and Tavassoli and Crosby [3] demonstrated that
heterotopically transplanted bone marrow formed both blood and
bone elements, identifying a source of progenitor cells of themesenchy-
mal and hematopoietic lineages. This work resulted in the pioneering
research by Friedenstein et al., who isolated speciﬁc cells within themi-
lieu of the bonemarrow responsible for stromal tissues, though the cur-
rent term “mesenchymal stem cell” was not coined until the early
1990's [4]. However, despite these discoveries in the 1960's and 70's,n and exclusion information.
605J. Feehan et al. / EBioMedicine 39 (2019) 603–611some details on the origin of osteoblasts have puzzled scientists. While
MSCs have been shown to differentiate into adult osteoblasts, it is un-
known how they access sites of bone formation non-contiguous to
bone marrow, rekindling the notion of a circulating osteoblastic
precursor.
Circulating cellswith some capacity formesenchymal differentiation
were identiﬁedmany years earlier [5], however theywere never shown
to produce bone tissue. It was not until 1997 that studies identiﬁed cir-
culating cells with osteoblastic characteristics in stem cell enriched
blood taken from breast cancer patients [6]. These cells were soon dem-
onstrated in healthy individuals at the turn of the 21st century, but
could not be prompted to form bone in vitro or in vivo, though they
did express several markers of osteogenesis and had hallmarks of the
previously identiﬁed bone marrow MSCs [7]. Demonstration for bone
formation capacity came soon in the pioneering work of Paolo Bianco
and Pamela Robey demonstrating in vivo ossiﬁcation shown after trans-
plantation of the cells into immunocompromised mice, and coining the
term circulating skeletal stem cell [8]. As the cells were similar in behav-
ior, appearance andmarker expression to the relativelywell understood
bonemarrowMSCs, they logically came to be considered as a closely re-
lated surrogate population of cells. However, shortly after, similar cells
which behaved and appeared similarly to bone marrow MSCs were
identiﬁed, but unlike MSCs, expressed hematopoietic lineage markers
[9,10]. This casts doubt on the origin of these cells – are they transitory
bonemarrowMSCs homing to sites of bone regeneration, or, are they of
the hematopoietic line, as the other themajor cell type involved in bone
turnover, the osteoclast? Alternatively, are there two populations pres-
ent in the circulation, and if so, what are their respective functions?
4. Characterization of COP cells
COP cells are known to exist within the peripheral blood mononu-
clear cell (PBMC) fraction of the blood, estimated to represent approxi-
mately 0.42% of this population [11]. and it appears that they circulate at
a steady level throughout the lifespan in healthy individuals, increasing
in times of accelerated bone growth [10,12], however their existence
has been refuted by one study [13]. Due to their similarities, MSCs are
commonly used as a comparison for COP cells. MSCs are typically classi-
ﬁed as being (i) plastic adherent, (ii) capable of multilineage differenti-
ation and logarithmic proliferation, (iii) expression of cell surface
markers, CD105, CD73, CD90, and (iv) not expressing the hematopoietic
markers CD34, CD45 and CD14 [14]. These qualities have been applied
to characterize COP cells, however, despite these common criteria,
there is still much contradiction between studies in regard to the ex-
pression of these markers. The characterization of COP cells varies
widely in many aspects, including their origin, marker expression, plas-
tic adherence, morphology, homing mechanism, differentiation and
proliferative potential.
5. Origins
Little deﬁnitive evidence exists regarding the speciﬁc cellular origin
of COP cells. However, it is widely believed that the bonemarrow is the
likely origin. Several studies speculate that COP cells are bone marrow
MSCs that have been stimulated to circulate by peripheral tissue de-
mands [6,7,15–18]. This is largely due to their similarities in behavior
and initialﬁndings on cell surfacemarker expression. This has been sup-
ported by parabiotic mouse models involving transplantation of green
ﬂuorescence protein positive (GFP+) bonemarrow into one paired an-
imal and stimulation of bone formation in the other [19,20]. Once oste-
ogenesis was initiated in the paired mouse, GFP+ cells were found at
the site of bone formation, indicating a circulating osteogenic cell,
though one studyof similarmethodologydid not identify the circulating
osteoprogenitors [13]. Despite this evidence that the bone marrow is
the tissue of origin, the precise cellular lineage of COP cells remains un-
clear. It has been suggested that hematopoietic stem cells (HSCs) arepossible progenitors for osteoblasts [21,22]. This, combined with
newer information on hematopoietic marker expression by COP cells,
suggests that COP cells may be an intermediary betweenHSCs and oste-
oblasts. Pignolo and Kassem [23] proposed amodel of both the hemato-
poietic and mesenchymal lineages beginning with an unknown
commonancestor progenitor cell. Itwasproposed that this commonan-
cestor gives rise to both HSCs andMSCs, before they both form their ac-
cepted terminal cells. The more recently discovered very small
embryonic-like (VSEL) stem cells have been shown to have the capacity
to regenerate tissue from all germ layers [24], and may be a candidate
for this unknown common progenitor. It was also suggested that COP
cells could fall directly under a number of ancestors including HSCs,
mesangioblasts and MSCs, as a heterogenous population of terminal
cell types, providing a possible explanation for the contradictory ﬁnd-
ings in the literature [23].
6. Marker expression
The identiﬁcation of speciﬁc cell surface markers or expression of
certain bone speciﬁc proteins has been a key point of contention in
COP cell research. The majority of the studies target two main groups
ofmarkers to characterize COP cells: proteins related to bone formation,
particularly osteocalcin (OCN), alkaline phosphatase (AP), and type one
collagen (Col1); andmarkers of the hematopoietic/vascular endothelial
line, largely centered on the pan-hematopoietic marker CD45, mono-
cytic marker CD14, and the endothelial stem cell marker CD34. While
there have been numerous other markers shown to be expressed, or
not expressed by COP cells, one or more of these feature inmost studies
examiningCOP cells. Despite these commonalities, there is little consen-
sus, and even outright contradiction, amongst authors regardingmarker
expression, particularly regarding the presence or absence of hemato-
poietic markers. Table 1 summarizes the range of marker combinations
used to characterize COP cells.
6.1. COP cells with MSC markers
Theﬁrst characterizations of COP cells described a population of cells
expressing the markers OCN, AP, and Col1, but not displaying CD45,
CD34 and CD14 [6–8]. This pattern of expression ﬁts within widely ac-
cepted criteria for the identiﬁcation of bone marrow MSCs, which are
typically described as being CD105, CD73, and CD90 positive, with co-
expression of the markers of osteogenesis above, and lacking the
CD45, CD34, and CD14 antigens [14]. Indeed, populations of circulating
cells ﬁtting exactly within these criteria have been identiﬁed in elderly
hip fracture patients [16], and postmenopausalwomenwith osteoporo-
sis [25]. Another study described a population of CD44 and osteopontin
(OPN) positive cells which also expressed Stro1, a marker believed to
identify bone marrow stromal cells [26]. It was also proposed that
these cellswere bonemarrowMSCs transiting to sites of bone formation
via the C-X-C chemokine receptor 4 (CXCR4)/stromal cell derived factor
1 (SDF-1) pathway [15].
The CXCR4/SDF-1 axis is a potent chemotactic pathway, and this
study proposed the CXCR4 receptor as a further means of identiﬁcation
of COP cells. Peripheral tissues factors have been shown to cause mobi-
lization of COP cells with markers similar so MSCs. The ﬁrst time these
cells were described was in response to growth factor mobilization, by
the intravenous administration of granulocyte colony stimulating factor
(G-CSF) or granulocyte-monocyte colony stimulating factor (GM-CSF).
These factors are used to mobilize granulocytes and HSCs from the
bonemarrow for cancer therapies, andwere shown to cause the release
of COP CD45-/CD34-/CD14- COP cells [6]. The inﬂammatory mediator
substance P has also demonstrated this capacity, stimulating the release
of a population of CD29+/CD45-/CD11b- stromal-like cells in the pe-
ripheral blood of rabbits after its intravenous administration [17].
Chronic hypoxia has also shown to cause COP cell mobilization with
CD44+/CD54+/CD73+/CD90+/CD45- cells mobilized into the
Table 1
Summary of marker strategies used to identify COP cells.
Study Hematopoietic
Markers
Other Markers Study Hematopoietic
Markers
Other
Markers
Kuzetnov et al., (2001) [8] CD45-
CD34-
CD14-
CD44+ OCN+ Col1+ Stro1-
OPN+
ON+
Egan et al. (2011 & 2018) [33,34] CD45+ OCN+, Col1+
Zvaiﬂer et al., (2000) [7] CD45-, CD34-, CD14- CD105+
OCN+
AP+
Col1+
Otsuru et al., (2017) [36] CD45+ Nil
Fernandez et al., (1997) [6] CD45-, CD34-, Col 1+ Suda et al., (2009) [35] CD45+ Col1+
Undale et al., (2010) [25] CD45-, CD14- AP+ Fadini et al., (2011) [47] CD45+
CD34-
CD14+
OCN+
AP+
Otsuru et al., (2008) [15] CD45- CD44+
OPN+
Stro1+ CXCR4+
Eghbali-Fatourechi et al., (2007) [12]
Pirro et al. (2010, 2011 & 2012) [38–40]
Rattazzi et al., (2016) [41]
CD34+ OCN+
AP+
Alm et al., (2010) [16] CD45-
CD34-
CD14-
CD105+, CD73+, CD90+ Manavalan et al., (2012) [44]
Rubin et al. (2011 & 2012) [43,45]
CD34+ OCN+
CD146+
Dalle Carbonare et al., (2009) [30] CD45+, CD34+, CD14+ Nil D'Amelio et al., (2010) [27]
Eghbali-Fatourechi et al., (2005) [10]
Nil OCN+
AP+
Kuwana et al., (2003) [9] CD45+, CD34+, CD14+ AP+ Col1+ Pal et al. (2010 & 2011) [43–44] Nil OCN+
Matsumoto et al., (2006) [78] CD45+, CD34+ CD31+, CD133+, CD105+ Boban et al., (2010) [13]
Kumagai et al., (2008) [20]
Otsuru et al., (2007) [19]
Nil GFP+
Ritz et al., (2014) [61] CD45+, CD34+ CD31+, CD133+ Kuzetnov et al., (2007) [46] Nil OPN+, BSP+,
ON+
Al Saedi et al., (2017) [32]
Gunawardene et al. (2015 & 2017) [11,31]
CD45+ OCN+ Wan et al., (2006) [48] Nil Nil
OCN: Osteocalcin, AP: Alkaline Phosphatase, Col1: Type 1 collagen, CXCR4: C-X-C chemokine receptor type 4, OPN: Osteopontin, BSP: Bone sialoprotein, ON: Osteonectin.
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cells are involved in processes of tissue injury, inﬂammation and
healing, being released from the bone marrow and circulating to sites
of repair, however much more research is required to validate this.
Taken together, this evidence appears to describe cells closely re-
lated to bone marrow MSCs which have been stimulated to mobilize
into the peripheral circulation, providing a logical explanation for the
genesis of these cells. However, a number of studies have noted circulat-
ing osteogenic cells which do not conform to the typical MSC identiﬁca-
tion criteria, expressing a range of hematopoietic markers raising
questions regarding the identity, behaviors and functions of COP cells.
Although the majority of research on COP cells has utilized a hema-
tological or vascular marker of some kind either by inclusion or exclu-
sion, a handful of studies have used only the expression of proteins
involved in bone formation as the criterion for the identiﬁcation and iso-
lation of COP cells. As such, OCN+ and AP+ cell behaviors have been
studied in times of pathologically or physiologically increased bone for-
mation, including puberty and fracture [10,27]. Others have simply used
OCN expression by PBMCs alone to classify COP cells and their relation-
ship to vascular calciﬁcation [28,29]. Whilst this approach has the ben-
eﬁt of simplicity, the lack of characterization of additional marker
expression makes the relationships of the cells studied unclear.
6.2. COP cells with hematopoietic and vascular markers
The ﬁrst cells to be identiﬁed as COP cells with hematopoietic
markers were coined monocyte-derived mesenchymal precursors.
They were shown to be CD45+/CD34+/CD14+/Col1+ cells and capa-
ble ofmultilineagemesenchymal differentiation and expansive prolifer-
ation [9]. In another study, a similar CD45+/CD34 + (low)population
was identiﬁed as COP cells, due to their expression of the genes coding
for osteoprotegerin (OPG) and receptor activator of nuclear factor
kappa-Β ligand (RANKL), both important markers of bone formation.
The cells identiﬁed in this study were heterogenous in their expression
of CD14 with a small proportion of the cells expressing the marker, and
the rest not [30]. More recently, the co-expression of CD45, OCN and/or
Col1 have been used to identify and characterize COP cells. Expression ofCD45+/OCN+ alongside the exclusion of CD3+ (T lymphocyte) and
CD19+(B lymphocyte) cells, has been used to studyCOP cells in a series
of experiments on their behavior in frail older adults [11,31,32]. Addi-
tion of themarker Col1 to the above criteria has also been used to isolate
COP cells in studies showing the role of COP cells in heterotopic ossiﬁca-
tion [33] and vascular calciﬁcation [34]. Furthermore, the role of CD45
+/Col1+ COP cells have been studied in the hereditary condition
Fibrodysplasia Ossiﬁcans Progressiva (FOP) [35]. This growing body of
evidence clearly shows the presence of COP cells with hematopoietic
markers, though the range of expression patterns studiedmakes it difﬁ-
cult to identify whether there is one, or many populations present.
Moreover, the biological behavior and functional signiﬁcance of
these cells is still unknown. Indeed, a recent study using a novel triple
transgenic mouse model has shown that while CD45+ COP cells were
recruited to sites of bone formation, they did not contribute to ossiﬁca-
tion via differentiation into osteoblasts [36]. They used mice with three
gene modiﬁcations – CD45-Cre, Z/RED and Col2.3GFP, which allowed
them to identify cells which had expressed CD45 at any time, even if it
was not currently present. While they showed the presence of these
CD45+ cells, and that their capacity to home to a site of bone morpho-
genic protein-2 (BMP2) mediated heterogenous ossiﬁcation (HO), they
did not differentiate into osteoblasts. The parallels between the expres-
sion of the hematopoietic lineage COP cells and the myeloid lineage os-
teoclast precursors coupled with this ﬁnding raises interesting
questions about their biological role. Their expression of markers of
bone formation implies an osteogenic role, even if it is not to differenti-
ate osteoblasts. It could be possible that they instead regulate the bal-
ance between osteoclastic resorption and osteoblastic activity,
directing the formation of bone. Thus, while hematopoietic cells with
osteogenic potential seem to exist in the circulation and be implicated
in states of bone formation or loss, their exact role is yet to be fully
determined.
Following the ﬁnding that the CD34+ fraction of the bone marrow
more reliably produced osteoblasts [37], expression of this endothelial
stem cell marker in conjunction with osteogenic markers has been
employed to isolate COP cells. One study found that there are two dis-
tinct populations amongst OCN+ cells: (i) CD34+ population, and (ii)
607J. Feehan et al. / EBioMedicine 39 (2019) 603–611CD34- population. The CD34+cells are smaller and less granular, whilst
the CD34- cells are large and dense. They proposed that they are not dif-
ferent populations, but that the change in expression occurs as the cells
mature and differentiate towards their terminal tissue, losing expres-
sion of CD34 as they lose their ‘stem’ capacity [12]. They also found
that the proportions of CD34 +/− cells changed as a function of ages,
with less CD34- cells present in older populations. Co-expression of
CD34 and OCN or AP has also been used to identify these cells in osteo-
porotic women, exploring the association between COP cell numbers
and rates of bone loss [38], arterial stiffness [39], thyroid hormones
[40] and the effect of the hypercholesterolemia medication atorvastatin
[41]. Cells with a CD34+/OCN+ phenotype in rates with artiﬁcially in-
duced tibial fractures. They described these cells as peaking in number
at three weeks post fracture, proposing them to have a role in the tran-
sition between the cartilaginous and mineralized callus [42]. Several
studies also used the endothelial and mesenchymal stem cell marker
CD146 to isolate COP cells to study their behavior in diabetic patients,
seeking to provide a rationale for the decrease in bonemass in type 2 di-
abetes mellitus [43–45]. The addition of markers classically associated
with vascular endothelium further complicates the landscape of COP
cells. The interaction between the bone, blood, and vascular lineages re-
mains unclear, however there seems to be some association between
the three in COP cell biology.
While there is a wide variance in the characterizations of COP cells,
some unifying themes can be identiﬁed. The literature appears to de-
scribe at least two distinct populations of COP cells, onewith a very sim-
ilar pattern ofmarker expression to bonemarrowMSCs, and at least one
other displaying surface receptors associated with the hematopoietic/
vascular lineages. These populations require further characterization
before they are fully understood. Additionally, the inconsistencies
within the literature should be explored, and each identiﬁed population
further studied for their functionality to determine their biological be-
havior and roles within normal physiology, as well as in pathological
conditions.
7. Plastic adherence
Plastic adherence is one of the central characteristics used to identify
bonemarrowMSCs. By commonly agreed on deﬁnition, MSCs must ad-
here to plastic in culture – a characteristic often shown to be shared by
COP cells [6–9,16,25,30,35,40,46–48]. However, the discovery of a non-
adherent cell population in the marrow expressing bone speciﬁc
markers [49,50], which has signiﬁcantly greater capacity for
regenerating bone [21] has prompted the examination of the non-
adherent PBMC fraction as well. Three other studies used this same
methodologywhen analyzing COP cell behavior [15,25,43]. These differ-
ences in adherence raise further questions regarding the nature of these
cells and their relationship to bone marrow MSCs, as more inconsis-
tencies between their biological behavior arise. It is currently unclear
whether the differences between adherent behavior correlates to differ-
ent patterns of observed marker expression, as well its functional
signiﬁcance.
8. Morphology
COP cell morphology has been documented in a number of studies.
They are typically described as small round cells initially, but become
elongated, “spindle shaped” or ﬁbroblast-like cells over 3–7 days in gen-
eral growthmedia [7,9,16,30]. Some studies have also reported a second
population of ﬂat or polygonal COP cells [8,48], though in one study it
was noted that these cells displayed a nearly identical panel of markers
to their ﬁbroblastic counterparts [8]. These spindle and ﬂat morphol-
ogies have been demonstrated in bone marrow MSCs, being shown to
represent different stages of differentiation, with the ﬂat cells being fur-
ther differentiated than their spindle shaped counterparts [51]. The ﬂat
cell morphology has not been identiﬁed in hematopoietic COP cells,though their morphology has only been described in a single study
[9]. Upon osteogenic differentiation, both hematopoietic and MSC-like
COP cells take on the characteristic rounded, cuboidal or “cobble
stone” appearance of osteoblasts [7,9], consistent with the morphologi-
cal behavior of bonemarrowMSCs. It is also yet unknown how themor-
phologies of these cells change in relation to external factors, such as
physiological stress, aging or time in passage. It has been demonstrated
that with increased number of passages, bone marrow MSCs become
broader and ﬂatter, with more numerous podia [52]. Additionally,
they appear to show decreased afﬁnity for the spindle morphology
with increasing lifespan, with a correlating decrease in differentiation
and proliferation capacity [53]. It is yet unknown whether these pat-
terns of aging are seen also in COP cells, or how they may affect the
cells functionally.
9. Differentiation potential
Differentiation into different mesenchymal tissues by COP cells has
been established in a number of studies. As might be expected, numer-
ous studies have shown osteoblastic differentiation potential of COP
cells, both in vitro and in vivo. Osteoblastic differentiation in vitro has
been demonstrated via a number of means including: staining of calci-
ﬁed nodules after culture [10,15,16,25,40,43,47,48], upregulation of
genes related to bone formation [30,43], and increased secretion of fac-
tors associated with osteogenesis [7,9,19]. Several studies have also
shown that these cells are osteogenic when injected or implanted on
pellets into mice, forming trabecular bone and some hematopoietic ele-
ments [8,15,35,46]. Evidence demonstrating multilineage capacity is
less frequent, but some studies have been able to demonstrate COP
cells forming tissues other than bone, showing them capable of in vitro
adipogenesis and chondrogenesis in humans [16–18,48] and guinea
pigs [46]. Interestingly, these authors were all experimenting on MSC-
like cells, with evidence demonstrating the same stem capacity in he-
matopoietic COP cells scarcer. Only one study has shown multilineage
differentiation in COP cells with hematopoietic markers, demonstrating
the in vitro formation of fat, muscle, and cartilage, in addition to bone
[9]. These authors provide support to the “stemness” of COP cells, how-
ever further investigation is necessary to understand the full extent of
their capacity for differentiation, particularly if and how it varies be-
tween the different subcategories of identiﬁed COP cells by marker ex-
pression. It is yet unknown how the differentiation of COP cells
compares with their bonemarrow or adipose tissue counterparts either
in vitro or in vivo in terms of the rate, extent and functionality. It has also
yet to be demonstrated how their differentiation is affected by external
variables such as patient age, culture conditions and number of pas-
sages. Bone marrow MSCs are known to undergo changes in differenti-
ation behavior throughout the lifespan, seemingly more inclined to
undergo adipogenesis than bone or muscle formation with increasing
age [54,55]. Additionally, bone marrow MSCs have been shown to
have the capacity to form tissues outside the traditional mesenchymal
lineages, such as neural cells [56], a capacity yet to be investigated in
COP cells. This information is essential in the evaluation of COP cells as
a potential target for diagnostic or therapeutic intervention.
10. Proliferative capacity
High capacity for proliferation is one of the hallmarks of a stem cell,
as it allows for generation of a large number of cells from a relative few,
enabling the maintenance of constant cellular turnover throughout the
life span. Proliferation is commonly assessed by calculation of popula-
tion doublings over time or with immunoﬂuorescent measures such
as the bromodeoxyuridine (BrdU) assay, giving an indication of how
rapidly, and expansively, a cell type can multiply [57,58]. Despite the
important role proliferation plays in the deﬁnition of a stem cell, only
few studies have assessed this quality in COP cells. COP cells have
been shown to have a similar capacity for proliferation as bonemarrow
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cells becoming6.7 ×10 [7] in 17days [7]. Another studywas able topas-
sage COP cells more than 6 times, and generate millions of additional
cells over that time, though no speciﬁc measurements were reported
[46]. The rate of proliferation over time has also been assessed in COP
cells. Using the BrdU assay one study showed that at ﬁrst passage ap-
proximately 50% of the COP cells were dividing, but declined to 5%
after ﬁve passages [9]. Of these four studies, three were assessing COP
cells which were similar in expression to MSCs [7,16,46], with only
one study examining COP cells with hematopoietic markers [9]. The
functional effect of proliferation has yet to be explored in COP cells.
For example, it is known that as the number of passages increase, the
ability of bone marrow MSCs to differentiate into their terminal cell
types is diminished as the cells become senescent [59]. It has also
been demonstrated that the secretome of MSCs changes depending on
number of passages, with later passage cells having increased inﬂam-
matory activity, cancer cell genesis and migration [59]. It is also impor-
tant to note that proliferation in vitro is tightly regulated,with stem cells
multiplying in response to peripheral demand, and entering a quiescent
state when the need has been met. This contrasts with a dedicated pro-
genitor cell, which is able tomultiply a certain number of times in order
to regenerate local cells [60]. While it appears that the MSC-like COP
cells exhibit behaviour more akin to stem cells, it is yet unclear how
their hematopoietic counterparts behave. These behaviors must be ex-
plored in COP cells in order for them to safely and effectively become
a viable option for medical use.
11. Cell homing
A key piece of information required for utilization of ex vivo cellular
therapies is the mechanism of cell homing, as it allows for locally
targeted therapies and reduces the risk of unintended effects in distant
tissues. Both hematopoietic andMSC-like COP cells have been shown to
bemobilized by a range of peripheral tissue states and factors including
fracture [16,20,27,61], thyroid hormones [43], substance P [17], and
hypoxia [18]. Themechanisms bywhich they home to sites of tissue for-
mation or repair still requiremuch investigation, although it is clear that
the CXCR4/SDF-1 plays a role in the process. A number of studies have
suggested this by identifying the CXCR4 surface membrane receptor
on these cells [15,35], by selectively inhibiting this receptor [15,47] or
demonstrating expression of the gene coding for the SDF-1 protein [7].
Additionally, COP cells have been shown to be mobilized by several
growth factors used medically to stimulate HSC migration in cancer pa-
tients [6]. That the CXCR4/SDF1 axis is also involved in the trafﬁcking of
theHSC and leukocyte populations [62] is yet another intriguing parallel
between cells of the hematopoietic and mesenchymal lineages worthy
of investigation. Despite this evidence supporting the CXCR4/SDF-1
axis as a homing mechanism for these cells, there are numerous other
avenues requiring investigation. It is not yet known how COP cells re-
spond to other common chemotactic factors related to tissue injury,
growth or development. MSCs are known to migrate in response to a
vast range of factors including platelet derived growth factor AB
(PDGF-AB), insulin-like growth factor 1 (IGF-1), and macrophage de-
rived chemokine (MDC) [63]. Additionally, the changes in cell homing
with increasing number passages must be evaluated, as bone marrow
MSCs are known to undergo a decrease in homing ability with increas-
ing expansions [64]. Full evaluation of how these cells target tissues is
vital to progress them to medical therapeutics, as well as to provide in-
sights into their physiological behaviors.
12. COP cells and bone marrow MSCs: outstanding questions
The similarity between COP cells and bone marrow MSCs is clear,
and as such they provide the most likely comparison population on
which to base future research. They appear to have similar morphol-
ogies and capacity for differentiation into mesenchymal tissues,however their patterns of surface marker expression seem to vary.
There are, however, many properties of MSCs that are unexplored in
COP cells. Perhaps most noteworthy of these are the effects and rela-
tionships with the human immune system. Bone marrow MSCs are
known to have a strong immunomodulatory effects in humans, with
suppressive effects on a range of immune cells, including T, B and natu-
ral killer cells and enhancement of macrophage activity via delay of ap-
optosis [65]. Additionally, it has been shown that MSCs possess the
capability of immune cell evasion, allowing them to be administered
to non-host organisms without risk of immune response and rejection
[66]. This is mediated by a number of mechanisms, including lack of
the major histocompatibility complex class II (MHCII) and related co-
stimulatory molecules [67], local immunosuppressive mechanisms
inhibiting immune cell activation via prostaglandin and interleukin sup-
pression [68], and direct modulation of lymphocyte and dendritic cell
function [69,70].
These immune effects are vital in the application of MSC therapeu-
tics, however no studies have evaluated these functions in COP cells. It
is also known that MSCs have a strong paracrine function in humans,
enabling them to have physiological or therapeutic effects in a diverse
range of tissues and diseases [71]. For example, paracrine effects of
MSCs have been credited for a large percentage of the cardioprotective
beneﬁt they confer in post-myocardial infarction patients [72]. It is
also demonstrated that the secretory and functional activity of MSCs
changes when the cells are placed under stress. For example, culture
of MSCs in an oxidative environment results in increased secretion of
antioxidant factors, providing evidence of their ability to respond to
local tissue demands [73].
The secretome of COP cells is currently completely unexplored, but
research in this area may identify mechanisms of therapeutic action
thus far unidentiﬁed, aswell as potentially broadening the scope of con-
ditions in which they have use. It is currently unknown whether COP
cells secrete any factors, or whether this behavior changes according
to local conditions. The evaluation and use of MSC therapies has also
been limited by the so called “pulmonary ﬁrst pass effect” in which sig-
niﬁcant numbers of intravenously injectedMSCs become trapped in the
lungs before reaching the target tissue [74]. Local therapeutic applica-
tion of COP cells has been investigated in an animal model with positive
results on fracture healing [48], however the fates of the injected cells
has not been assessed, so whether they are subject to this effect is
unknown.
While the literature surrounding COP cells is still sparse, some pre-
liminary conclusions can be drawn regarding their characterization.
Firstly, it is apparent that there are at least two major populations pres-
ent – a cell population that is very similar in most areas to a bone mar-
row MSC, and another discrete population with similar behavior, but
expressing hematopoietic markers (Fig. 1). The MSC-like COP cells ap-
pear to be rarer [7,8,46] and they may only circulate in response to pe-
ripheral factors associated with tissue damage and repair, such as
substance P [17], hypoxia [18], or SDF-1 [15]. These cells express a
very similar panel of surface markers to bone marrowMSCs, do not ex-
press hematopoietic markers such as CD45, 34, or 14, and are similar, if
not identical, to MSCs in behavior and appearance. The second popula-
tion has been more extensively researched but is also possibly less
well understood due to the divergent methods of identiﬁcation and
analysis. It is currently unclear as to whether this group is made up of
one cell type or multiple, as researchers have not used consistent strat-
egies for identiﬁcation and isolation. It appears that the population ex-
presses some combination of CD45, CD34, and CD14, as well as the
markers of bone formationOCN, Col1, and AP. This pattern of expression
is unique compared to other known circulating adherent cell types such
as endothelial stem cells (CD34+/CD45-) [75], and macrophages
(CD34-) [76] though is similar to that of ﬁbrocytes. While the behavior
of ﬁbrocytes and COP cells is distinct, more research is required to iden-
tify the relationships and roles of these two cell types, particularly given
the ability of ﬁbrocytes to differentiate into osteoblasts in vitro [77].
Fig. 2. Summary of known and unknown information in COP cells biology.
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they behave similarly to MSCs, however, conﬁrmation and exploration
of their proliferative and differentiation capacity is required, alongside
careful characterization of their marker expression. Hematopoietic
COP cells have been associated with several states of physiological or
pathological bone formation, such as puberty and fracture [10], osteo-
porosis [38–40], and frailty [31,32], indicating that these cells may be
a diagnostic or therapeutic target for use in managing these conditions.
It has frequently been identiﬁed that the isolation and extraction of COP
cells is a difﬁcult task due to their poorly understood expression of
markers, and their low frequencies [23]. While MSC like COP cells are
consistently shown to be rare, and likely circulate only in response to
peripheral injury or demand [8,16], hematopoietic COP cells have
been shown to circulate in greater numbers [12] and at a steady state
throughout the lifespan [11] perhaps providing a greater reservoir to
draw upon for culture. There is also minimal evidence demonstrating
that they can be sufﬁciently expanded and manipulated once cultured,
providing further hurdles to their use in therapeutic settings, particu-
larly in the case of hematopoietic COP cells. While much remains un-
known, it is clear that cells of the blood, vascular and bone lineages
are more physiologically connected than once thought, and further
study must be done to explore the interplay between these tissues.
13. Conclusions
COP cells have profound and exciting implications for future use,
particularly in the area of regenerative medicine and the treatment
and assessment of musculoskeletal disease. An easily accessible reser-
voir of stem cells in adult patients would overcome many hurdles in
the therapeutic or diagnostic application of these cells. Removal of
blood carries signiﬁcant advantages over bone marrow biopsy in risk
and patient comfort, making stem cell therapies a more feasibletreatment strategy. However, before they can be applied in medical set-
tings, signiﬁcantly further understanding of their biological nature,
morphological, and functional properties is required. Future research
must therefore, further examine the different cell populations identiﬁed
in the literature, fully characterizing both, as well as determining their
respective physiological roles, behaviors, and interactions. Once this is
achieved, it will provide a foundation upon which future research on
the role of COP cells in pathology can be based, providing consistency
amongst researchers as to the precise identity of the populations
being studied.
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